title: Implanted microvessels progress through distinct neovascularization phenotypes.
abstract: We have previously demonstrated that implanted microvessels form a new microcirculation with minimal host-derived vessel investment. Our objective was to define the vascular phenotypes present during neovascularization in these implants and identify post-angiogenesis events. Morphological, functional and transcriptional assessments identified three distinct vascular phenotypes in the implants: sprouting angiogenesis, neovascular remodeling, and network maturation. A sprouting angiogenic phenotype appeared first, characterized by high proliferation and low mural cell coverage. This was followed by a neovascular remodeling phenotype characterized by a perfused, poorly organized neovascular network, reduced proliferation, and re-associated mural cells. The last phenotype included a vascular network organized into a stereotypical tree structure containing vessels with normal perivascular cell associations. In addition, proliferation was low and was restricted to the walls of larger microvessels. The transition from angiogenesis to neovascular remodeling coincided with the appearance of blood flow in the implant neovasculature. Analysis of vascular-specific and global gene expression indicates that the intermediate, neovascular remodeling phenotype is transcriptionally distinct from the other two phenotypes. Therefore, this vascular phenotype likely is not simply a transitional phenotype but a distinct vascular phenotype involving unique cellular and vascular processes. Furthermore, this neovascular remodeling phase may be a normal aspect of the general neovascularization process. Given that this phenotype is arguably dysfunctional, many of the microvasculatures present within compromised or diseased tissues may not represent a failure to progress appropriately through a normally occurring neovascularization phenotype.
authors.affiliation: Cardiovascular Innovation Institute, University of Louisville and Jewish Hospital/St. Mary's Healthcare, Louisville, KY 40202, USA.
authors.forename: Sara S
authors.initials: SS
authors.lastname: Nunes
authors.forename: Kevin A
authors.initials: KA
authors.lastname: Greer
authors.forename: Chad M
authors.initials: CM
authors.lastname: Stiening
authors.forename: Helen Y S
authors.initials: HY
authors.lastname: Chen
authors.forename: Kameha R
authors.initials: KR
authors.lastname: Kidd
authors.forename: Mark A
authors.initials: MA
authors.lastname: Schwartz
authors.forename: Chris J
authors.initials: CJ
authors.lastname: Sullivan
authors.forename: Harish
authors.initials: H
authors.lastname: Rekapally
authors.forename: James B
authors.initials: JB
authors.lastname: Hoying
mesh_terms: D000273:Adipose Tissue / Q000098:blood supply*; D000818:Animals; D017209:Apoptosis; D002465:Cell Movement; D049109:Cell Proliferation; D005260:Female; D005786:Gene Expression Regulation; D049452:Green Fluorescent Proteins / Q000235:genetics; D008297:Male; D051379:Mice; D016513:Mice, SCID; D008822:Mice, Transgenic; D008833:Microcirculation; D055806:Microvessels / Q000637:transplantation*; D018919:Neovascularization, Physiologic / Q000235:genetics; D010641:Phenotype; D025341:Principal Component Analysis; D013997:Time Factors; D014158:Transcription, Genetic
chemical_list: D049452:Green Fluorescent Proteins